Dossier assessment
Sacituzumab govitecan (breast cancer) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Sacituzumab govitecan (breast cancer) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Sacituzumab govitecan (breast cancer) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least 2 additional systemic therapies in the advanced setting
Hint of minor added benefit
Press releases
Early benefit assessment: Informative RCTs are also feasible in later lines of oncological treatment
Additional information
Federal Joint Committee (G-BA)
2024-02-15 A G-BA decision was published.
Project details
- Project no.
- A23-86
- Commission
- Commission awarded on 15.08.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://dx.doi.org/10.60584/A23-86
Connected Projects
-
Dossier assessment
Sacituzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Sacituzumab govitecan (breast cancer) – Addendum to Project A23-86
Status: Commission completed
-
Dossier assessment
Sacituzumab govitecan (breast cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed